Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Rosuvastatin on par with atorvastatin in CAD
Rosuvastatin is as effective as atorvastatin for the composite outcome of all-cause death, myocardial infarction (MI), stroke, or any coronary revascularization at 3 years in adults with coronary artery disease (CAD), according to the secondary analysis of the LODESTAR trial.
Rosuvastatin on par with atorvastatin in CAD
06 Nov 2023
Does intermittent fasting reduce acid exposure in GERD patients?
Patients with suspected gastroesophageal reflux disease (GERD) may find it difficult to follow a time-restricted eating, reports a study. Additionally, there is weak evidence to suggest that intermittent fasting helps ease acid exposure.
Does intermittent fasting reduce acid exposure in GERD patients?
06 Nov 2023
Cefazolin beneficial in infective endocarditis caused by methicillin-susceptible S aureus
In the treatment of patients with methicillin-susceptible S aureus (MSSA)-associated infective endocarditis, the cefazolin is as good as cloxacillin, with similar mortality and relapse rates, according to a study.
Cefazolin beneficial in infective endocarditis caused by methicillin-susceptible S aureus
06 Nov 2023
Adding pembrolizumab to cCRT ups PFS in high-risk locally advanced cervical cancer
In patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, adding pembrolizumab to concurrent chemoradiotherapy (cCRT) significantly improves progression-free survival (PFS) vs cCRT alone, according to results of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study presented at European Society for Medical Oncology Congress 2023 (ESMO 2023).
Adding pembrolizumab to cCRT ups PFS in high-risk locally advanced cervical cancer
06 Nov 2023
IBS symptoms tied to depression, anxiety in NAFLD patients
Patients with nonalcoholic fatty liver disease (NAFLD) tend to have higher rates of irritable bowel syndrome (IBS) symptoms, depression, and anxiety, suggests a study.
IBS symptoms tied to depression, anxiety in NAFLD patients
04 Nov 2023
Add-on immunotherapy prolongs survival in advanced endometrial cancer
In the treatment of patients with advanced or recurrent endometrial carcinoma, adding the PD-L1 inhibitor atezolizumab to chemotherapy helps lower the risk of progression or death, according to the phase III AtTEnd trial.